Logo image of RSLS

RESHAPE LIFESCIENCES INC (RSLS) Stock Fundamental Analysis

NASDAQ:RSLS - Nasdaq - US76090R3093 - Common Stock - Currency: USD

0.3385  -0.01 (-1.74%)

Premarket: 0.343 +0 (+1.33%)

Fundamental Rating

1

Taking everything into account, RSLS scores 1 out of 10 in our fundamental rating. RSLS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of RSLS have multiple concerns. RSLS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RSLS had negative earnings in the past year.
In the past year RSLS has reported a negative cash flow from operations.
RSLS had negative earnings in each of the past 5 years.
In the past 5 years RSLS always reported negative operating cash flow.
RSLS Yearly Net Income VS EBIT VS OCF VS FCFRSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -148.76%, RSLS is doing worse than 89.42% of the companies in the same industry.
Industry RankSector Rank
ROA -148.76%
ROE N/A
ROIC N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RSLS Yearly ROA, ROE, ROICRSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K 3K

1.3 Margins

RSLS has a Gross Margin of 63.17%. This is in the better half of the industry: RSLS outperforms 62.96% of its industry peers.
RSLS's Gross Margin has improved in the last couple of years.
RSLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
RSLS Yearly Profit, Operating, Gross MarginsRSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RSLS has been increased compared to 1 year ago.
RSLS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for RSLS is higher compared to a year ago.
RSLS Yearly Shares OutstandingRSLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
RSLS Yearly Total Debt VS Total AssetsRSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

RSLS has an Altman-Z score of -190.29. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RSLS (-190.29) is worse than 96.83% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -190.29
ROIC/WACCN/A
WACC8.67%
RSLS Yearly LT Debt VS Equity VS FCFRSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RSLS has a Current Ratio of 0.92. This is a bad value and indicates that RSLS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.92, RSLS is doing worse than 91.53% of the companies in the same industry.
A Quick Ratio of 0.43 indicates that RSLS may have some problems paying its short term obligations.
The Quick ratio of RSLS (0.43) is worse than 93.65% of its industry peers.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.43
RSLS Yearly Current Assets VS Current LiabilitesRSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

RSLS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.83%.
RSLS shows a decrease in Revenue. In the last year, the revenue decreased by -7.79%.
RSLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.54% yearly.
EPS 1Y (TTM)-45.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.41%
Revenue 1Y (TTM)-7.79%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-8.93%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RSLS Yearly Revenue VS EstimatesRSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
RSLS Yearly EPS VS EstimatesRSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RSLS. In the last year negative earnings were reported.
Also next year RSLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RSLS Price Earnings VS Forward Price EarningsRSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RSLS Per share dataRSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RSLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RESHAPE LIFESCIENCES INC

NASDAQ:RSLS (4/30/2025, 8:00:01 PM)

Premarket: 0.343 +0 (+1.33%)

0.3385

-0.01 (-1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-13 2025-05-13
Inst Owners4.1%
Inst Owner Change0%
Ins Owners5.18%
Ins Owner Change0%
Market Cap3.82M
Analysts43.33
Price TargetN/A
Short Float %9.6%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-27.31%
Min Revenue beat(2)-44.22%
Max Revenue beat(2)-10.4%
Revenue beat(4)0
Avg Revenue beat(4)-19.2%
Min Revenue beat(4)-44.22%
Max Revenue beat(4)-9.41%
Revenue beat(8)0
Avg Revenue beat(8)-15.86%
Revenue beat(12)0
Avg Revenue beat(12)-16.28%
Revenue beat(16)0
Avg Revenue beat(16)-14.3%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.67
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.71
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -148.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.17%
FCFM N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
F-Score3
Asset Turnover1.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.43
Altman-Z -190.29
F-Score3
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)11.32%
Cap/Depr(5y)20.35%
Cap/Sales(3y)0.55%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.41%
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.79%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-8.93%
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.9%
OCF growth 3YN/A
OCF growth 5YN/A